Patents Assigned to The General Hospital Corporation
-
Patent number: 11964017Abstract: Described herein are compositions comprising, and methods for using, biocompatible cold slurries and methods of administering the same to provide reversible inhibition of peripheral nerves in a subject in need thereof.Type: GrantFiled: October 16, 2023Date of Patent: April 23, 2024Assignee: The General Hospital CorporationInventors: Lilit Garibyan, Richard Rox Anderson, William A. Farinelli, Emilia Javorsky
-
Patent number: 11967070Abstract: An image analysis system including at least one processor and at least one memory is provided. The image analysis system is configured to receive image data associated with a brain of a patient, the image data including a first three-dimensional (3D) diffusion weighted imaging (DWI) image acquired using a magnetic resonance imaging (MRI) system and a second 3D DWI image, concurrently provide the first 3D DWI image to a first channel of a trained model and the second 3D DWI image to a second channel of the trained model, receive an indicator associated with the first 3D DWI image and the second 3D DWI image from the model, generate a report based on the indicator, and cause the report to be output to at least one of a memory or a display.Type: GrantFiled: May 13, 2020Date of Patent: April 23, 2024Assignee: The General Hospital CorporationInventors: Hakan Ay, Jayashree Kalpathy-Cramer
-
Patent number: 11963661Abstract: In some embodiments, systems, methods, and media for capsule-based multimode endoscopy are provided. In some embodiments, a probe for capsule-based multimode endoscopy is provided, the probe comprising: a rigid capsule; a flexible tether coupled to a proximal end of the capsule; a rotatable reflective surface disposed within the capsule; a static ball lens disposed within the capsule; a first optical fiber optically coupled to the ball lens, the first optical fiber passing through the flexible tether; a second optical fiber optically coupled to the ball lens, the second optical fiber passing through the flexible tether; a graded index fiber disposed between a distal end of the second optical fiber and the ball lens, the graded index fiber optically coupled to the second optical fiber and the ball lens.Type: GrantFiled: December 16, 2022Date of Patent: April 23, 2024Assignee: The General Hospital CorporationInventors: Guillermo J. Tearney, Kanwarpal Singh
-
Publication number: 20240124924Abstract: The present disclosure relates to methods and compositions for enhanced assessment of exogenous polynucleotide and/or polypeptide-mediated transcriptional perturbations at high throughput and single cell/droplet levels of resolution. In embodiments, nucleic acid fusions of exogenous polynucleotide(s) and associated target transcript(s) are produced within individually sequestered or discretely identifiable cells/lysates and analyzed for exogenous polynucleotide mediated perturbations across a vast population of droplets/cells within individual reactions. Kits for performance of the methods are also provided.Type: ApplicationFiled: February 22, 2022Publication date: April 18, 2024Applicants: THE BROAD INSTITUTE, INC., MASSACHUSETTS INSTITUTE OF TECHNOLOGY, THE GENERAL HOSPITAL CORPORATIONInventors: Aziz Al'Khafaji, Frances Keer, Paul Blainey, Nir Hacohen
-
Patent number: 11958887Abstract: The invention provides compositions and methods for treating tuberous sclerosis complex (TSC). In particular, provided are condensed tuberins (cTuberins), cTuberin nucleic acids, and recombinant adeno-associated viruses (rAAVs) carrying a cTuberin nucleic acid for treating a patient with TSC.Type: GrantFiled: May 17, 2018Date of Patent: April 16, 2024Assignee: The General Hospital CorporationInventors: Xandra Breakefield, Casey Maguire, Shilpa Prabhakar, David Yellen
-
Publication number: 20240117440Abstract: The invention provides a molecular classifier and a targeted sequencing assay for use in characterization and treatment of diffuse large B-cell lymphoma.Type: ApplicationFiled: September 15, 2023Publication date: April 11, 2024Applicants: The Broad Institute, Inc., Dana-Farber Cancer Institute, Inc., The General Hospital CorporationInventors: Bjoern CHAPUY, Donald STEWART, Tim WOOD, Margaret SHIPP, Gad GETZ, Mark MURAKAMI, Lee LAWTON, Andrew DUNFORD, Kirsty WIENAND
-
Publication number: 20240115187Abstract: A system and a method is provided for assessing motion of a biological tissue of a subject including one or more superficial biological layers and a targeted biological layer. A perturbation unit provide an optical perturbation to the one or more superficial biological layers. An optical signal generator transmits optical signals at one or more near-infrared wavelengths. An optical signal receiver acquires a set of optical signal data preceding, during, or following the optical perturbation at a first acquisition time relative to the optical perturbation. A signal processor determines, using the set of optical signal data, a set of optical characteristics and separates, using the set of optical characteristics, a target optical signal. The signal processor generates a report indicative of a movement of the targeted biological tissue within the subject. The movement of the targeted biological layer is calculated using the target optical signal.Type: ApplicationFiled: December 13, 2023Publication date: April 11, 2024Applicant: The General Hospital CorporationInventors: Quan Zhang, Gary Strangman
-
Patent number: 11944971Abstract: A microfluidic device includes a particle sorting region having a first, second and third microfluidic channels, a first array of islands separating the first microfluidic channel from the second microfluidic channel, and a second array of islands separating the first microfluidic channel from the third microfluidic channel, in which the island arrays and the microfluidic channels are arranged so that a first fluid is extracted from the first microfluidic channel into the second microfluidic channel and a second fluid is extracted from the third microfluidic channel into the first microfluidic channel, and so that particles are transferred from the first fluid sample into the second fluid sample within the first microfluidic channel.Type: GrantFiled: April 30, 2021Date of Patent: April 2, 2024Assignee: The General Hospital CorporationInventors: Ravi Kapur, Kyle C. Smith, Mehmet Toner
-
Patent number: 11948311Abstract: A combined physics-based and machine learning framework is used for reconstructing images from k-space data, in which motion artifacts are significantly reduced in the reconstructed images. In general, model-based retrospective motion correction techniques are accelerated using fast machine learning (“ML”) steps, which may be implemented using a trained neural network such as a convolutional neural network. In this way, the confidence of a classical physics-based reconstruction is obtained with the computational benefits of an ML-based network.Type: GrantFiled: March 26, 2020Date of Patent: April 2, 2024Assignee: The General Hospital CorporationInventors: Stephen Cauley, Melissa Haskell, Lawrence Wald
-
Patent number: 11944972Abstract: A microfluidic device includes: a first microfluidic channel; a second microfluidic channel extending along the first microfluidic channel; and a first array of islands separating the first microfluidic channel from the second microfluidic channel, in which each island is separated from an adjacent island in the array by an opening that fluidly couples the first microfluidic channel to the second microfluidic channel, in which the first microfluidic channel, the second microfluidic channel, and the islands are arranged so that a fluidic resistance of the first microfluidic channel increases relative to a fluidic resistance of the second microfluidic channel along a longitudinal direction of the first microfluidic channel such that, during use of the microfluidic device, a portion of a fluid sample flowing through the first microfluidic channel passes through one or more of the openings between adjacent islands into the second microfluidic channel.Type: GrantFiled: June 1, 2021Date of Patent: April 2, 2024Assignee: The General Hospital CorporationInventors: Ravi Kapur, Kyle C. Smith, Mehmet Toner
-
Patent number: 11946040Abstract: Engineered adenine base editor (ABE) variants with reduced RNA editing activity, and methods of using the same.Type: GrantFiled: February 4, 2020Date of Patent: April 2, 2024Assignee: The General Hospital CorporationInventors: J. Keith Joung, Julian Grunewald, Ronghao Zhou
-
Patent number: 11939369Abstract: Provided herein are integrin antagonists and methods of using the same. For example, one or more of the compounds or polypeptides provided herein can be used in the treatment of disorders such as heart attacks, stroke, and cancer metastasis.Type: GrantFiled: July 30, 2021Date of Patent: March 26, 2024Assignee: The General Hospital CorporationInventor: M. Amin Arnaout
-
Patent number: 11939637Abstract: In one aspect, provided herein is a method comprising: (a) (i) determining cytolytic activity in a tumor from the subject; and/or (ii) determining genetic alterations associated with cytolytic activity in the tumor; and (b) administering an immunotherapeutic agent to the subject if (i) cytolytic activity is detected in the tumor and/or (ii) a genetic alteration associated with induction of cytolytic activity, tumor resistance to cytolytic activity and/or suppression of cytolytic activity is detected in the tumor.Type: GrantFiled: February 19, 2021Date of Patent: March 26, 2024Assignees: Massachusetts Institute of Technology, The General Hospital CorporationInventors: Nir Hacohen, Michael S. Rooney
-
Patent number: 11938188Abstract: One aspect of the invention provides a slurry comprising: a plurality of sterile ice particles having a largest cross-sectional dimension less than about 1.5 mm; and a biocompatible surfactant. Another aspect of the invention provides a slurry including: a plurality of sterile ice particles having a largest cross-sectional dimension less than about 1.5 mm; a biocompatible surfactant; and a foam comprising a plurality of gas bubbles. Another aspect of the invention provides a slurry including: a plurality of sterile ice particles having a largest cross-sectional dimension less than about 1.5 mm; and a biocompatible excipient. Another aspect of the invention provides a slurry including: a plurality of sterile ice particles having a largest cross-sectional dimension less than about 1.5 mm; and a lipolytic agent.Type: GrantFiled: March 1, 2021Date of Patent: March 26, 2024Assignee: The General Hospital CorporationInventors: Lilit Garibyan, Richard Rox Anderson, William A. Farinelli, Emilia Javorsky
-
Patent number: 11939571Abstract: Expressing guide nucleic acids (e.g., gRNA) from the same oligonucleotide that contains donor sequence permits the high efficiency, simultaneous transformation of a population of cells with both substrates. Using oligonucleotide chip array technology, one can construct thousands of oligonucleotides with customized gRNA and donor sequence in a cost effective manner. In combination, one can efficiently modify endogenous and exogenous genes.Type: GrantFiled: June 12, 2017Date of Patent: March 26, 2024Assignees: President and Fellows of Harvard College, The General Hospital CorporationInventors: Xiaoge Guo, Alejandro Chavez, Max Schubert, Eric Kelsic
-
Publication number: 20240091316Abstract: The present application relates to novel methods for preventing, slowing the progression of, or treating nonalcoholic fatty liver (NAFL), nonalcoholic steatohepatitis (NASH), and/or liver fibrosis, and/or reducing the risks of liver cancer in subjects, such as HIV-infected subjects, using a GHRH molecule, e.g., trans-3-hexenoyl-GHRH(1-44)-NH2, or a pharmaceutically acceptable salt thereof. The subjects may have particular pathological features such as liver fibrosis, a hepatic fat fraction (HFF) of at least about 10%, serum alanine aminotransferase (ALT) levels of at least about 30 U/L, and/or a NAFLD Activity Score (NAS) of at least 4 or 5.Type: ApplicationFiled: July 12, 2023Publication date: March 21, 2024Applicant: The General Hospital CorporationInventor: Steven K. GRINSPOON
-
Publication number: 20240091213Abstract: Provided herein are bifunctional compounds that bind tau protein and/or promote targeted ubiquitination for the degradation of tau protein. In particular, provided are compounds that can bind tau protein, a protein whose aggregation is implicated in a variety of neurodegenerative disease (e.g., tauopathies), and can promote its degradation by recruiting an E3 ubiquitin ligase (e.g., Cereblon), which can ubiquitinate tau protein, marking it for proteasomal degradation. Also provided are radiolabeled forms of the bifunctional compounds, pharmaceutical compositions comprising the bifunctional compounds, methods of detecting and/or diagnosing neurological disorders, methods of detecting and/or diagnosing pathological aggregation of tau protein (e.g., in the central nervous system), methods of treating and/or preventing neurological disorders, and methods of promoting the degradation of tau protein by E3 ubiquitin ligase activity in a subject by administering a compound or composition described herein.Type: ApplicationFiled: May 23, 2023Publication date: March 21, 2024Applicants: DANA-FARBER CANCER INSTITUTE, INC., THE GENERAL HOSPITAL CORPORATION d/b/a MASSACHUSETTS GENERAL HOSPITALInventors: Nathanael S. Gray, Stephen J. Haggarty, Quan Cai, Tinghu Zhang, Maria Catarina Telo Baptista Lima da Silva, Fleur M. Ferguson
-
Publication number: 20240084286Abstract: This disclosure provides a method for substantially increasing the concentration of cfDNA in a patient. By injecting a patient with lipid and/or polymer nanoparticles, agents that bind cfDNA, or inhibit deoxyribonucleases prior to collection of a sample of cfDNA, e.g., by way of a liquid biopsy, major pathways for the degradation of cfDNA are temporarily blocked, permitting transient accumulation of cfDNA. This strategy has the potential to dramatically enhance the quality of detection achieved by downstream cfDNA e analytical applications, such as sequencing applications.Type: ApplicationFiled: January 25, 2022Publication date: March 14, 2024Applicants: The Broad Institute, Inc., Massachusetts Institute of Technology, The General Hospital CorporationInventors: Viktor A. Adalsteinsson, Shervin Tabrizi, Sangeeta N. Bhatia, J. Christopher Love, Maria Carmen Martin Alonso, Kan Xiong
-
Publication number: 20240082315Abstract: Provided herein are methods and compositions comprising a bacterium or a metabolite thereof for enhancing mitochondrial and/or peroxisomal function.Type: ApplicationFiled: July 12, 2023Publication date: March 14, 2024Applicant: The General Hospital CorporationInventors: Gary RUVKUN, J. Amaranath Govindan, Elamparithi Jayamani
-
Patent number: 11926849Abstract: Ex vivo monolayer models of human interstinal epithelia that express sensors, and methods of use thereof for evaluation of the effects of test compounds on the human gut.Type: GrantFiled: March 30, 2020Date of Patent: March 12, 2024Assignees: The General Hospital Corporation, Massachusetts Institute Of TechnologyInventors: Alessio Fasano, Timothy K. Lu, Stefania Senger, Maria Eugenia Inda